World Osteoporosis day is coming up on October 20, so in light of this we present our top articles discussing osteoporosis as well as other associated conditions such as fibromyalgia, kidney stones, psoriasis, heart disease, and breast cancer.
Osteoporosis is a bone disease that commonly affects women – as well as men. Osteoporosis typically develops in older age and is characterized by a loss of bone mass, which makes the bones weak and brittle. This increases the risk of fractures, potentially leading to further complications.
The goal of World Osteoporosis Day is to raise awareness while offering prevention tips for the bone disease.
Fibromyalgia may raise osteoporosis risk
Fibromyalgia may raise the risk of osteoporosis. A condition characterized by widespread pain, fibromyalgia can result in limited mobility and lack of sunlight exposure – factors that increase the likelihood of osteoporosis in a patient.
Osteoporosis is a bone disease characterized by the loss of bone mass. Factors that contribute to bone strength include exercising, eating calcium-rich foods, and getting adequate amounts of vitamin D, which is easily absorbed through sun exposure.
In the latest study, researchers evaluated vitamin D serum levels and bone mineral density in female fibromyalgia patients and healthy women.
Recurrent kidney stone patients at higher risk of heart disease and osteoporosis
Recurrent kidney stone patients are at a higher risk of heart disease and osteoporosis. The findings suggest that close monitoring of recurring kidney stones could help protect patients from heart-related problems.
Nearly 10 percent of men and seven percent of women will develop kidney stones, and over the last few decades mounting evidence has shown that individuals who have experienced kidney stones have an increased risk of developing other conditions, including hypertension, chronic kidney disease, and heart disease, but the mechanisms involved were long unknown.
The researchers speculate that the rise of heart-related conditions due to recurring kidney stones may be associated with abnormal calcium deposits in the blood vessels. Vascular calcification is strongly correlated with heart-related disease and death.
Psoriasis and general bone loss linked, may help osteoporosis treatment research: Study
Psoriasis and general bone loss have been found to be linked and studies suggest it may help osteoporosis treatment research. Researchers from the Genes, Development and Disease Group found that psoriasis patients experience higher levels of bone loss as a result of the disease.
Their findings, published in Science Translational Medicine, described the molecular communication that is established between the inflamed skin and loss of bone mass. The research unveiled a possible treatment for psoriasis with already available drugs that could benefit bone health, too.
Psoriasis is an autoimmune disorder that affects two percent of the world’s population. Manifested as inflammation and scaling of the skin, psoriasis increases a person’s risk of developing a type of metabolic syndrome by predisposing them to obesity, cardiovascular disease, and diabetes.
Osteoporosis linked to coronary heart disease in older people, both could have similar causes: Study
A potential new risk of heart disease has just been discovered. In fact, it has to do with osteoporosis.
If you’re over the age of 50, you’re at higher risk of developing osteoporosis – women and men alike. Osteoporosis is when the bones in our body become weak and brittle and can increase the risk of fractures.
You may not think a bone disease may affect your heart, but it does. This link between the two diseases is according to a new study by the University of Southampton.
Osteoporosis drug denosumab may lower breast cancer risk in women: Study
Osteoporosis drug denosumab may lower breast cancer risk in women, according to research. The Australian researchers found that women who have a high risk of breast cancer may greatly benefit from a bone loss drug as it was found to halt cancer cell growth contributing to tumors. Women with the BRCA1 gene mutation are at a greater risk for breast cancer, compared to women without it.
The research is still at its early stages, so you won’t find denosumab commonly prescribed as a means to lower breast cancer rates just yet. The findings must first be reproduced in a large human trial.
When BRCA1 and BRCA2 genes are healthy, they work to repair DNA, but if either gene develops a mutation, the risk of ovarian and breast cancers increases.